Petar Vazharov is the Chief Executive Officer of Lotus and responsible for leading Lotus's management and business expansion, and strategic execution.
Mr. Vazharov has over 30 years of Pharma industry experience. He spent nine years with the generic pharmaceutical company Actavis Group in various roles and has demonstrated his ability to lead the CEE business. In 2020, he started to lead Lotus to expand its global business and formulate a complete market strategy to achieve long-term and stable growth goals.
After the deal that Aztiq and Innobic became the main shareholders of Lotus, Petar said: "We are so excited to kick off another new chapter of Lotus's journey with the combined efforts from industry veteran and regional leader. Lotus has achieved several major milestones and is now the largest generic company in Taiwan. Again, this transaction is a testimonial for all the achievements Lotus has made during the past few years and great recognition by these two long-term partners for Lotus. Innobic and Aztiq will support Lotus's existing strategy and fuel the growth by bringing new opportunities, experience, and resources."
Petar graduated with a medical doctor's degree from Sofia University of Medicine in 1999 and has an MBA degree from the University of Sofia "Kliment Ohridski" in October 2007.